Literature DB >> 26238001

Incorrect diagnosis of Clostridium difficile infection in a university hospital in Japan.

Nobuaki Mori1, Sadako Yoshizawa2, Tomoo Saga1, Yoshikazu Ishii3, Hinako Murakami4, Morihiro Iwata4, Deirdre A Collins5, Thomas V Riley6, Kazuhiro Tateda7.   

Abstract

Physicians often fail to suspect Clostridium difficile infection (CDI) and many microbiology laboratories use suboptimal diagnostic techniques. To estimate the extent of and reasons for incorrect diagnosis of CDI in Japan, we investigated toxigenic C. difficile isolated from all stool culture samples and clinical course. Over a 12-month period in 2010, all stool culture samples (n = 975) submitted from inpatients in a university hospital in Japan were cultured for C. difficile and routine microbiological testing was conducted. In total, 177 C. difficile isolates were recovered, and 127 isolates were toxigenic. Among the toxin-A-positive/toxin-B-positive isolates, 12 were also positive for the binary toxin gene. However, clinically important ribotypes, such as 027 and 078, were not identified. A total of 58 (45.7%) cases with toxigenic C. difficile had unformed stool, and the incidence CDI was 1.6 cases per 10,000 patient-days. Of these 58 cases, 40 were not diagnosed in routine testing due to a lack of clinical suspicion (24.1%, 14/58) or a negative C. difficile toxin assay result (44.8%, 26/58). A stool toxin assay was performed in 54 patients (78.2%, 54/69) who did not have unformed stool. The present study demonstrated that a significant number of CDI cases in Japan might be overlooked or misdiagnosed in clinical practice due to a lack of clinical suspicion and limitations of microbiological testing for CDI in Japan. Providing education to promote awareness of CDI among physicians is important to improve the accuracy of diagnosis in Japan.
Copyright © 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Binary toxin; Clostridium difficile infection; Epidemiology; Incorrect diagnosis; PCR ribotype

Mesh:

Substances:

Year:  2015        PMID: 26238001     DOI: 10.1016/j.jiac.2015.06.009

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  6 in total

Review 1.  The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review.

Authors:  Thomas V Riley; Tomomi Kimura
Journal:  Infect Dis Ther       Date:  2018-02-13

2.  Clostridioides difficile infection in the Asia-Pacific region.

Authors:  Deirdre A Collins; Kyung Mok Sohn; Yuan Wu; Kentaro Ouchi; Yoshikazu Ishii; Briony Elliott; Thomas V Riley; Kazuhiro Tateda
Journal:  Emerg Microbes Infect       Date:  2019-12-24       Impact factor: 7.163

3.  Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile.

Authors:  Deirdre A Collins; Yuan Wu; Kazuhiro Tateda; Hee-Jung Kim; Richard J Vickers; Thomas V Riley
Journal:  J Antimicrob Chemother       Date:  2021-03-12       Impact factor: 5.790

4.  Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults.

Authors:  Osamu Matsuoka; Dhaval M Patel; Shin Sasaki; Hayato Oka; Toru Sasaki; Patricia J Pietrobon; Thelma Laot; Alain Bouckenooghe; Josemund Menezes; Guy de Bruyn
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

5.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

6.  Excess length of hospital stay, mortality and cost attributable to Clostridioides (Clostridium) difficile infection and recurrence: a nationwide analysis in Japan.

Authors:  T Kimura; S Stanhope; T Sugitani
Journal:  Epidemiol Infect       Date:  2020-03-02       Impact factor: 2.451

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.